My research utilizes pharmacokinetic/pharmacodynamic and systems pharmacology approaches that integrates a systems perspective, mechanistic mathematical modeling and simulation with quantitative experimental lab studies to advance the discovery, development, and clinical use of drugs.
Education and Training:
Postdoctoral Fellow, National Cancer Institute (NCI) (2010)
PhD, Pharmaceutical Sciences, State University of New York at Buffalo (2007)
MS, Pharmacokinetics, Chungnam National University (2001)
BPharm, Pharmacy, Chungnam National University (1999)
Employment:
Adjunct Associate Professor, Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center (2020-present)
Associate Professor, Pharmaceutical Sciences, University at Buffalo (2019-present)
Associate Professor, Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, College of Pharmacy (2017–2019)
Investigator, Stephenson Cancer Center at OUHSC (2010–2019)
Assistant Professor, Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, College of Pharmacy (2010–2017)
Postdoctoral Fellow, Center for Cancer Research, National Cancer Institute, NIH (2008–2010)
Awards and Honors:
Edith Kinney Gaylord Presidential Professorship, University of Oklahoma (2019)
Research Scholar Award, American Cancer Society (2016)
Young Investigator Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism/Clinical Pharmacology Translational Research, AAPS (2013)
Cancer Research Training Award Fellowship, Center for Cancer Research, NCI/NIH (2008)
Graduate Scholar Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism/Clinical Pharmacology Translational Research Section, AAPS (2007)
AAPS Annual Meeting Travels Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPDM) (2006)
2006 Graduate Scholar Award, Pharmaceutical Science, University at Buffalo (2006)
Teaching Assistant Award, Pharmaceutical Sciences, University at Buffalo (2004)
Dongbu Foundation Scholarship (1997)
Research Expertise:
Anticancer drug development, ovarian cancer
Pharmacokinetics and Pharmacodynamics
Quantitative systems pharmacology (QSP) approaches: integrates a systems perspective, mechanistic mathematical modeling and simulation with quantitative experimental lab studies to advance the discovery, development, and clinical use of drugs.
Grants and Sponsored Research:
December 2021–November 2026 Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition NIH-National Cancer Institute (NCI) Role: Principal Investigator $2,000,000
September 2021–August 2022 Evaluating the Effect of Target Properties on Anti-cancer siRNA Therapeutics Center for Protein Therapeutics Role: Principal Investigator $100,000
July 2016–June 2022 Overcoming resistance to anti-VEGF therapy with predictive modeling American Cancer Society Role: Principal Investigator $792,000
June 2016–May 2022 Targeting HPV Consequences in a Cervical Cancer Clinical Trial NIH/NCI Role: Co-Investigator $2,755,370
December 2016–November 2021 Reprograming Tumor Microenvironment by Nanoparticle NIH/NCI Role: Co-Investigator $1,143,750
March 2015–January 2021 Photo-unclick Chemistry and Its Application to Near Infrared-activatable Prodrugs NIGMS/NIH Role: Co-Investigator $1,784,850
August 2017–July 2020 Visible Light-Controlled Combination Strategy for Treating Nonmuscle Invasive Bladder Cancers DOD CDMRP/PRCRP Role: Co-Investigator $529,000
July 2015–June 2020 Ovarian Cancer Chemoprevention NCI/NIH Role: Co-Investigator $3,072,192
September 2015–September 2018 PREVENT Cancer Preclinical Drug Development NIH/NCI Role: Co-Investigator $1,888,965
March 2016–June 2017 Gynecology Oncology Drug Development Fund Stephenson Cancer Center Role: Principal Investigator
September 2012–May 2017 Tumor resistant mechanisms to anti-VEGF therapy NIGMS/NIH Role: Principal Investigator $612,000